CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 14, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its decision to advance its pandemic flu project as a development program, adding to the company’s growing pipeline of RNAi therapeutics. Alnylam also announced that it has received initial government funding for the program from the Department of Defense’s ‘Defense Advanced Research Projects Agency’ (DARPA). Alnylam expects to submit an investigational new drug (IND) application for an RNAi therapeutic for pandemic flu as early as the end of 2006.
